CY1117547T1 - Ενωση πυραζολοκινολινης - Google Patents
Ενωση πυραζολοκινολινηςInfo
- Publication number
- CY1117547T1 CY1117547T1 CY20161100451T CY161100451T CY1117547T1 CY 1117547 T1 CY1117547 T1 CY 1117547T1 CY 20161100451 T CY20161100451 T CY 20161100451T CY 161100451 T CY161100451 T CY 161100451T CY 1117547 T1 CY1117547 T1 CY 1117547T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bladder
- pde9
- inhibitory activity
- compound
- dysuria
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Για παροχή μίας ένωσης η οποία έχει ΡDΕ9-ανασταλτική δραστικότητα και είναι χρήσιμη ως ένα δραστικό συστατικό ενός παράγοντα για αντιμετώπιση και/ή πρόληψη υπερδραστήριας ουροδόχου κύστης, δυσουρίας, νόσου της ουροδόχου κύστης και του ουροποιητικού συστήματος, και των παρόμοιων. [Λύση] Οι εφευρέτες της παρούσας εφεύρεσης μελέτησαν ενώσεις οι οποίες έχουν ΡDΕ9-ανασταλτική δραστικότητα και είναι χρήσιμες ως δραστικά συστατικά παραγόντων για αντιμετώπιση και/ή πρόληψη υπερδραστήριας ουροδόχου κύστης, δυσουρίας, νόσου της ουροδόχου κύστης και του ουροποιητικού συστήματος, και των παρόμοιων, και τελειοποίησαν την παρούσα εφεύρεση επιβεβαιώνοντας ότι οι ενώσεις πυραζολοκινολίνης έχουν PDE9-ανασταλτική δραστικότητα. Η ένωση πυραζολοκινολίνης της παρούσας εφεύρεσης έχει ΡDΕ9-ανασταλτική δραστικότητα και μπορεί να χρησιμοποιηθεί ως ένας παράγοντας για πρόληψη και/ή αντιμετώπιση υπερδραστήριας ουροδόχου κύστης, δυσουρίας, νόσου της ουροδόχου κύστης και του ουροποιητικού συστήματος, και των παρόμοιων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010200403 | 2010-09-07 | ||
EP11823618.1A EP2615089B1 (en) | 2010-09-07 | 2011-09-07 | Pyrazoloquinoline compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117547T1 true CY1117547T1 (el) | 2017-04-26 |
Family
ID=45810740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100451T CY1117547T1 (el) | 2010-09-07 | 2016-05-24 | Ενωση πυραζολοκινολινης |
Country Status (18)
Country | Link |
---|---|
US (1) | US8822448B2 (el) |
EP (1) | EP2615089B1 (el) |
JP (1) | JP5888237B2 (el) |
KR (1) | KR101860583B1 (el) |
CN (1) | CN103097383B (el) |
BR (1) | BR112013005444B1 (el) |
CA (1) | CA2810696C (el) |
CY (1) | CY1117547T1 (el) |
DK (1) | DK2615089T3 (el) |
EA (1) | EA023493B1 (el) |
ES (1) | ES2583528T3 (el) |
HR (1) | HRP20160473T1 (el) |
HU (1) | HUE028038T2 (el) |
MX (1) | MX2013002584A (el) |
PL (1) | PL2615089T3 (el) |
RS (1) | RS54834B1 (el) |
SI (1) | SI2615089T1 (el) |
WO (1) | WO2012033144A1 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2573073T3 (pl) * | 2011-09-26 | 2015-04-30 | Sanofi Sa | Pochodne pirazolochinolinonu, ich wytwarzanie i ich zastosowanie terapeutyczne |
US9169246B2 (en) * | 2011-09-26 | 2015-10-27 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
RU2605096C2 (ru) * | 2011-10-07 | 2016-12-20 | ЭЙСАЙ АрЭНДДи МЕНЕДЖМЕНТ КО., ЛТД. | Пиразолохинолиновое производное |
CN102786525B (zh) | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
SG11201507733YA (en) | 2013-04-05 | 2015-10-29 | Eisai R&D Man Co Ltd | Pyridinylpyrazoloquinoline compound |
CA2907971C (en) * | 2013-04-05 | 2020-12-29 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AR102849A1 (es) * | 2015-03-09 | 2017-03-29 | Astellas Pharma Inc | Compuesto de piridina bicíclica |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2018276565A1 (en) | 2017-06-01 | 2019-11-07 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
SG10202113199RA (en) | 2017-06-01 | 2021-12-30 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
RU2019135261A (ru) | 2017-06-01 | 2021-07-09 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция, содержащая ингибитор pde9 |
BR112019023552A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina |
IL312114A (en) | 2021-10-14 | 2024-06-01 | Incyte Corp | Quinoline compounds as Kras inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192768A (en) | 1990-09-14 | 1993-03-09 | Kyowa Hakko Kogyo Co., Ltd. | Pyrazoloquinoline derivatives |
JPH05132484A (ja) * | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | ピラゾロキノリン及びピラゾロナフチリジン誘導体 |
HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
NZ541232A (en) | 2003-01-09 | 2008-02-29 | Astellas Pharma Inc | Pyrrolopyridazine derivatives |
TW200508233A (en) | 2003-05-29 | 2005-03-01 | Millennium Pharm Inc | Chk-1 inhibitors |
JP2006045118A (ja) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | 新規ピラゾロキノロン誘導体 |
ES2526701T3 (es) | 2005-06-14 | 2015-01-14 | Aska Pharmaceutical Co., Ltd. | Derivado de tienopirimidina |
US7671069B2 (en) | 2006-03-30 | 2010-03-02 | Chemocentryx, Inc. | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 |
AU2007282678B2 (en) | 2006-08-08 | 2012-09-27 | Aska Pharmaceutical Co., Ltd. | Quinazoline derivative |
ES2536906T3 (es) | 2006-12-13 | 2015-05-29 | Aska Pharmaceutical Co., Ltd. | Derivado de quinoxalina |
CN101557826A (zh) | 2006-12-13 | 2009-10-14 | Aska制药株式会社 | 泌尿***疾病的治疗药 |
JP4579346B2 (ja) | 2007-05-11 | 2010-11-10 | ファイザー・インク | アミノ複素環式化合物 |
US8648085B2 (en) | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
NZ590788A (en) | 2008-09-08 | 2012-11-30 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of cns disorders |
US9259564B2 (en) | 2009-01-22 | 2016-02-16 | Avent, Inc. | Enteral feeding assembly with lock assembly |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
-
2011
- 2011-09-07 WO PCT/JP2011/070410 patent/WO2012033144A1/ja active Application Filing
- 2011-09-07 DK DK11823618.1T patent/DK2615089T3/en active
- 2011-09-07 SI SI201130826A patent/SI2615089T1/sl unknown
- 2011-09-07 EP EP11823618.1A patent/EP2615089B1/en active Active
- 2011-09-07 RS RS20160364A patent/RS54834B1/sr unknown
- 2011-09-07 CA CA2810696A patent/CA2810696C/en active Active
- 2011-09-07 BR BR112013005444-1A patent/BR112013005444B1/pt not_active IP Right Cessation
- 2011-09-07 MX MX2013002584A patent/MX2013002584A/es active IP Right Grant
- 2011-09-07 ES ES11823618.1T patent/ES2583528T3/es active Active
- 2011-09-07 KR KR1020137005776A patent/KR101860583B1/ko active IP Right Grant
- 2011-09-07 PL PL11823618.1T patent/PL2615089T3/pl unknown
- 2011-09-07 CN CN201180043183.XA patent/CN103097383B/zh active Active
- 2011-09-07 EA EA201390353A patent/EA023493B1/ru not_active IP Right Cessation
- 2011-09-07 HU HUE11823618A patent/HUE028038T2/en unknown
- 2011-09-07 JP JP2012533012A patent/JP5888237B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-07 US US13/788,907 patent/US8822448B2/en active Active
-
2016
- 2016-05-04 HR HRP20160473TT patent/HRP20160473T1/hr unknown
- 2016-05-24 CY CY20161100451T patent/CY1117547T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2615089A1 (en) | 2013-07-17 |
SI2615089T1 (sl) | 2016-08-31 |
JPWO2012033144A1 (ja) | 2014-01-20 |
PL2615089T3 (pl) | 2016-10-31 |
EP2615089A4 (en) | 2014-01-01 |
EA201390353A1 (ru) | 2013-08-30 |
EP2615089B1 (en) | 2016-04-27 |
ES2583528T3 (es) | 2016-09-21 |
CA2810696A1 (en) | 2012-03-15 |
CN103097383A (zh) | 2013-05-08 |
JP5888237B2 (ja) | 2016-03-16 |
CA2810696C (en) | 2018-09-18 |
EA023493B1 (ru) | 2016-06-30 |
HRP20160473T1 (hr) | 2016-07-29 |
BR112013005444A2 (pt) | 2017-09-19 |
MX2013002584A (es) | 2013-04-29 |
RS54834B1 (sr) | 2016-10-31 |
US20130225553A1 (en) | 2013-08-29 |
CN103097383B (zh) | 2015-09-16 |
HUE028038T2 (en) | 2016-11-28 |
KR20130106358A (ko) | 2013-09-27 |
KR101860583B1 (ko) | 2018-05-23 |
BR112013005444B1 (pt) | 2019-07-09 |
US8822448B2 (en) | 2014-09-02 |
DK2615089T3 (en) | 2016-06-06 |
WO2012033144A1 (ja) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117547T1 (el) | Ενωση πυραζολοκινολινης | |
CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
EA201270566A1 (ru) | Противомикробные соединения и способы их получения и применения | |
EA201100873A1 (ru) | Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания | |
NO20092444L (no) | Heteroarylamidderivater | |
EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
BRPI1009860A2 (pt) | composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais | |
CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
CN107406464A8 (zh) | 精氨酸酶抑制剂及其治疗用途 | |
MX2013003638A (es) | Tratamiento en combinacion para rosacea. | |
WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
BR112015026840A2 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia | |
BRPI0920251A2 (pt) | composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto. | |
MX2019004484A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
MX2009011819A (es) | Formulaciones de aminoacido n-halogenado. | |
UY31058A1 (es) | Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios | |
MX2009011817A (es) | Formulaciones de aminoacido n-halogenado que contienen acido alifatico. |